HRS 2189
Alternative Names: HRS-2189Latest Information Update: 15 Jul 2025
At a glance
- Originator Shandong Suncadia Medicine
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Breast cancer
- Phase I Solid tumours
Most Recent Events
- 01 Jul 2025 Fudan University plans a phase II trial for Colorectal cancer (Metastatic disease, Combination therapy) in July 2025 (PO) (NCT07061210)
- 21 Jan 2025 Phase-I/II clinical trials in Breast cancer (Combination therapy, Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in China (PO) (NCT06679036)
- 18 Dec 2024 Fudan University plans a phase II trial for Prostate cancer (Metastatic disease, Combination therapy) in China (PO) (NCT06738745)